Respiratory Syncytial Virus Antibody (9C5): sc-52183
- Respiratory Syncytial Virus Antibody (9C5) is a mouse monoclonal IgG2b provided at 100 µg/ml
- raised against purified respiratory syncytial virus, strain Long
- recommended for detection of F protein of RSV of Respiratory Syncytial Virus origin by ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Respiratory Syncytial Virus Antibody (9C5). This work is in progress.
QUICK LINKS
SEE ALSO...
Respiratory Syncytial Virus Antibody (9C5) is a mouse monoclonal IgG2b antibody that specifically detects Respiratory Syncytial Virus (RSV) by enzyme-linked immunosorbent assay (ELISA). RSV is a significant pathogen, particularly in infants and young children, leading to severe respiratory illnesses. RSV fusion protein (9C5) monoclonal antibody enables researchers to study the protein′s crucial role in viral infection, where RSV fusion protein mediates the merging of viral envelope with host cell membrane, allowing viral genome entry. RSV fusion protein (9C5) antibody helps investigate the formation of syncytia - large, multinucleated cells that disrupt normal tissue function and trigger immune responses. RSV fusion protein (9C5) monoclonal antibody serves as an invaluable tool for researchers studying viral protein function and developing targeted therapies and vaccines against RSV-related respiratory diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Respiratory Syncytial Virus Antibody (9C5) References:
- The changing landscape of respiratory syncytial virus. | Polack, FP. 2015. Vaccine. 33: 6473-8. PMID: 26247900
- Reverse Genetics of Respiratory Syncytial Virus. | Stobart, CC., et al. 2016. Methods Mol Biol. 1442: 141-53. PMID: 27464692
- Respiratory syncytial virus mortality among young children. | Weinberg, GA. 2017. Lancet Glob Health. 5: e951-e952. PMID: 28911753
- Antibiotic Minocycline Prevents Respiratory Syncytial Virus Infection. | Bawage, SS., et al. 2019. Viruses. 11: PMID: 31405261
- miRNAs and Leukotrienes in Respiratory Syncytial Virus Infection. | Liu, Z., et al. 2021. Front Pediatr. 9: 602195. PMID: 33996675
- Receptors for Respiratory Syncytial Virus Infection and Host Factors Regulating the Life Cycle of Respiratory Syncytial Virus. | Feng, Z., et al. 2022. Front Cell Infect Microbiol. 12: 858629. PMID: 35281439
- Structural landscape of the respiratory syncytial virus nucleocapsids. | Gonnin, L., et al. 2023. Nat Commun. 14: 5732. PMID: 37714861
- Nirsevimab to reduce infant morbidity from respiratory syncytial virus. | Abu-Raya, B., et al. 2024. CMAJ. 196: E1114-E1117. PMID: 39353638
- Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. | Xu, H., et al. 2025. JAMA Netw Open. 8: e250380. PMID: 40063022
- Respiratory syncytial virus immunology. | Kimpen, JL. 1996. Pediatr Allergy Immunol. 7: 86-90. PMID: 9156738
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Respiratory Syncytial Virus Antibody (9C5) | sc-52183 | 100 µg/ml | $316.00 |